Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

NCT02044822 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion

Interventions

DRUG: Idelalisib
DRUG: Rituximab

Sponsor

Gilead Sciences